New Approach for Antiviral Development
A new antiviral modeling approach combines various experimental techniques to create a comprehensive picture of a virus' dynamic behavior.
Tag: RSV respiratory syncytial virus
All
Latest
New Approach for Antiviral Development
A new antiviral modeling approach combines various experimental techniques to create a comprehensive picture of a virus’ dynamic behavior.
Read More
RSV Vaccine Program for Seniors Cut Hospitalizations by 62%
An RSV vaccine program targeted at seniors in Scotland found 68% of adults aged 75-79 were vaccinated which led to a 62% reduction in RSV-related hospitalizations.
Read More
FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Read More
American Confidence in RSV Vaccines Rises, Survey Finds
A new Annenberg Public Policy Center survey reveals evolving public attitudes toward vaccines—including RSV, flu, COVID-19, and MMR—in the United States.
Read More
RSV Vaccine Effectiveness Lower in Immunocompromised Older Adults
Johns Hopkins Medicine says further research is needed to better understand the problem and find ways to enhance immune response in this high-risk population.
Read More
N95 Masks Can Reduce COVID-19 Transmission Risk by Ninefold: Study
High-quality face masks, such as N95/FFP2, can lower the risk of COVID-19 transmission by up to nine times when used by the entire UK population and by three times with individual use, according to a new study.
Read More
Best Window for RSV Vaccination During Pregnancy Identified
Current guidelines recommend RSV vaccination between 32-36 weeks of pregnancy, but researchers have identified the optimal time within that window for maximum newborn protection.
Read More
EPA Updates Indoor Air Quality Guidance
The EPA has released updated guidance on indoor air quality strategies for preventing the spread of common respiratory viruses.
Read More
New CMS Rule Requires Weekly Respiratory Data Reporting from Hospitals
Starting Nov 1, Medicare- and Medicaid-participating hospitals must report COVID-19, influenza, and RSV data to the CDC on a weekly basis.
Read More
Pfizer’s RSV Vaccine Approved for Adults Down to Age 18
The FDA has approved Pfizer’s RSV vaccine, Abrysvo, for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV, expanding its previous indication for adults aged 60 and older.
Read More
Arexvy RSV Vaccine Shows Protection Over Three Seasons
Cumulative efficacy over three RSV seasons was clinically meaningful at 62.9% against RSV-LRTD after a single dose of the vaccine.
Read More
Respiratory Viruses Can Hide Out in Lungs’ Immune Cells Long After Infection
Researchers say these lingering viruses may be why some children develop chronic respiratory conditions, as they create a persistently inflammatory environment that promotes the development of lung disease.
Read More
COVID-19, Flu and RSV Shots − An Epidemiologist Explains Why All Three Matter This Fall
Epidemiologist Annette Regan explains why officials recommend that people get these shots over the coming months.
Read More
Americans’ Willingness to Get COVID-19 Vaccines Declines, Survey Finds
A survey found that 44% of Americans are likely to get a yearly COVID-19 vaccine if recommended by the CDC, a drop from 52% just eight months earlier.
Read More
RSV Is Linked to Asthma in Children – But We Can’t Say One Causes the Other Yet
While respiratory syncytial virus, or RSV, is strongly associated with asthma in children, the exact relationship remains unclear.
Read More
ACP Urges Adults to Get Recommended Vaccinations
The American College of Physicians is advising adults to get all recommended vaccines to protect against preventable diseases and reduce the spread of infection.
Read More
Pfizer’s RSV Vaccine Shows Promise in Immunocompromised Adults
Pfizer’s Abrysvo demonstrated a strong immune response and favorable safety profile in immunocompromised adults at high risk of severe RSV.
Read More
Wearable Alerts for Respiratory Infections Spur Few to Get Tested
While wearables can detect potential respiratory infections, a new study shows that only a quarter of individuals follow up with at-home testing.
Read More
Merck’s Investigational RSV Shot Protects Infants in Phase 2b/3 Trial
The trial showed that clesrovimab reduced RSV-related respiratory infections in infants through day 150.
Read More
FDA Clears Biofire Spotfire Respiratory/Sore Throat Panel Mini
bioMérieux’s Biofire Spotfire Respiratory/Sore Throat (R/ST) Panel Mini received US FDA Special 510(k) clearance and CLIA-waiver, according to the company.
Read More
Under 75? CDC Revises RSV Vaccine Recommendations for High-Risk Only
The CDC’s updated guidance recommends vaccination only for high-risk adults aged 60-74, while strengthening its advice for adults 75 and older.
Read More
FDA Expands Approval of Arexvy for Adults Age 50-59
GlaxoSmithKline’s RSV vaccine Arexvy is now available for at-risk adults age 50-59 in addition to those age 60 and older.
Read More
FDA Approves Moderna RSV Vaccine
mRESVIA is the first mRNA vaccine approved for a disease other than COVID-19 and is the only RSV vaccine available in single-dose pre-filled syringes.
Read More
FDA Authorizes Roche 4-in-1 Test for SARS-CoV-2, Influenza A/B, RSV
The FDA issued emergency use authorization to Roche’s cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test, the company reports.
Read More